Atrial fibrillation (AF) is a comorbidity of a variety of other chronic, inflammatory diseases for
which fibrinaloid microclots are a known accompaniment (and in some cases, a cause, with …

Background: Heart failure is a prevalent and life-threatening medical condition characterized
by abnormal atrial electrical activity, contributing to a higher risk of ischemic stroke. Atrial …

Introduction The clinical outcomes of direct oral anticoagulant (DOAC) dosage regimens in
morbid obesity are uncertain due to limited clinical evidence. This study seeks to bridge this …

Aim This study aimed to evaluate the label compliance of DOACs in the Chinese AF
population and explore the relationship between inappropriate DOACs dosage and clinical …

Background The prognostic impact of obesity on patients with atrial fibrillation (AF) remains
under-evaluated and controversial. Methods Patients with AF from the Gulf Survey of Atrial …

Objective Through predictable pharmacokinetics—including a convenient fixed-dose
regimen, direct oral anticoagulants (DOACs) are preferred over previous treatments in …

Background: Despite data derived from observational studies, optimal anticoagulation
strategies have yet to be established for patients with nonvalvular atrial fibrillation and …

Background Based on the few available studies on the prognostic benefit of using direct oral
anticoagulants (DOACs) after atrial fibrillation (AF) ablation. Therefore, this study aimed to …

Background: There are few studies on using rivaroxaban and low molecular heparin
(LMWH) to prevent venous thromboembolism (VTE) in hospitalized cancer patients …

Abstract The popularity of Direct Oral AntiCoagulants (DOACs) for approved indications has
risen dramatically following their introduction to the UK's National Health Service (NHS) due …